CN1744917B - 经肺给药用缓释性制剂学组合物 - Google Patents

经肺给药用缓释性制剂学组合物 Download PDF

Info

Publication number
CN1744917B
CN1744917B CN200480003325XA CN200480003325A CN1744917B CN 1744917 B CN1744917 B CN 1744917B CN 200480003325X A CN200480003325X A CN 200480003325XA CN 200480003325 A CN200480003325 A CN 200480003325A CN 1744917 B CN1744917 B CN 1744917B
Authority
CN
China
Prior art keywords
carrageenan
pharmaceutical composition
pharmacologically active
active substance
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480003325XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1744917A (zh
Inventor
山本昌
山田圭吾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1744917A publication Critical patent/CN1744917A/zh
Application granted granted Critical
Publication of CN1744917B publication Critical patent/CN1744917B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200480003325XA 2003-02-26 2004-02-25 经肺给药用缓释性制剂学组合物 Expired - Fee Related CN1744917B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003049019 2003-02-26
JP049019/2003 2003-02-26
PCT/JP2004/002193 WO2004075920A1 (ja) 2003-02-26 2004-02-25 経肺投与用徐放性製剤学的組成物

Publications (2)

Publication Number Publication Date
CN1744917A CN1744917A (zh) 2006-03-08
CN1744917B true CN1744917B (zh) 2010-05-05

Family

ID=32923305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480003325XA Expired - Fee Related CN1744917B (zh) 2003-02-26 2004-02-25 经肺给药用缓释性制剂学组合物

Country Status (9)

Country Link
US (1) US20060078504A1 (https=)
EP (1) EP1600170A4 (https=)
JP (1) JPWO2004075920A1 (https=)
KR (1) KR20050105490A (https=)
CN (1) CN1744917B (https=)
CA (1) CA2512434C (https=)
MY (1) MY142361A (https=)
TW (1) TW200500085A (https=)
WO (1) WO2004075920A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150810A1 (en) * 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
PL2178533T3 (pl) * 2007-08-24 2013-08-30 Marinomed Biotechnologie Gmbh Kompozycja przeciwwirusowa zawierająca siarczanowany polisacharyd: jota-karagen
CA2726221C (en) * 2008-07-01 2017-03-28 Marinomed Biotechnologie Gmbh Antiallergic marine biopolymers
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066078A2 (en) * 2001-02-15 2002-08-29 Aeropharm Technology, Inc. Modulated release particles for aerosol delivery
WO2002066008A1 (en) * 2001-02-15 2002-08-29 Aeropharm Technology, Inc. Modulated release particles for aerosol delivery
WO2002085385A2 (en) * 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
JP2000070327A (ja) * 1998-09-01 2000-03-07 Kao Corp 鼻腔内洗浄具
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
NL1015288C2 (nl) * 2000-05-24 2001-12-14 Peter Ferdinand Elbers Preparaat voor het stabiliseren van de beschermlaag op het epitheel van het hoornvlies of de longblaasjes.
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
JP2002255852A (ja) * 2001-03-01 2002-09-11 Toa Eiyo Ltd 口内炎用スプレー製剤
JP2003040766A (ja) * 2001-07-26 2003-02-13 Kao Corp 鼻腔内洗浄具

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066078A2 (en) * 2001-02-15 2002-08-29 Aeropharm Technology, Inc. Modulated release particles for aerosol delivery
WO2002066008A1 (en) * 2001-02-15 2002-08-29 Aeropharm Technology, Inc. Modulated release particles for aerosol delivery
WO2002085385A2 (en) * 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa

Also Published As

Publication number Publication date
EP1600170A4 (en) 2010-12-29
TW200500085A (en) 2005-01-01
TWI332403B (https=) 2010-11-01
MY142361A (en) 2010-11-30
HK1083768A1 (zh) 2006-07-14
JPWO2004075920A1 (ja) 2006-06-01
CA2512434C (en) 2012-01-03
EP1600170A1 (en) 2005-11-30
KR20050105490A (ko) 2005-11-04
US20060078504A1 (en) 2006-04-13
CN1744917A (zh) 2006-03-08
CA2512434A1 (en) 2004-09-10
WO2004075920A1 (ja) 2004-09-10

Similar Documents

Publication Publication Date Title
Liu et al. Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation
Park et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols
US7625865B2 (en) Insulin highly respirable microparticles
EP0895473B1 (en) Polysaccharide microspheres for the pulmonary delivery of drugs
ES2205560T5 (es) Preparaciones estabilizadas para usar en inhaladores de dosis medida
Tam et al. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution
US8080263B2 (en) Dispersion for pulmonary delivery of a bioactive agent
Wan et al. Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying
JP2009532489A (ja) 薬剤微粒子
El-Gendy et al. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols
PT1259228E (pt) Composições terapêuticas para distribuição pulmonar
CN1744917B (zh) 经肺给药用缓释性制剂学组合物
Peštálová et al. Modern trends in the formulation of microparticles for lung delivery using porogens: methods, principles and examples
JP5437543B2 (ja) 喘息検出用製剤
US20080292713A1 (en) Respirable Powders
KR20040093155A (ko) 흡입용 분말 의약조성물 및 이의 제조방법
HK1083768B (en) Sustained-release pharmaceutical composition for lung administration
US20030099601A1 (en) Inhalation lung surfactant therapy
CN121648089A (zh) 一种缓释的西维来司他组合物及其制备方法
KR102259824B1 (ko) 보센탄을 함유한 약학 제제
HK40116441A (zh) 可吸入团聚纳米颗粒乾粉药物组合物、及其制备方法和用途
WO2023281404A1 (en) Controlled release injectable cariprazine formulation
WO2006095788A1 (ja) 粒子およびその粒子を含有する製剤
MXPA00003106A (en) Stabilized bioactive preparations and methods of use
JPWO2001028517A1 (ja) 水性医薬品組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083768

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1083768

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100505

Termination date: 20130225